
HROW Stock Forecast & Price Target
HROW Analyst Ratings
Bulls say
Harrow is poised for strong future growth as they continue to develop and acquire new eye care products, with a sales guidance of $350M-$360M for 2026 and a longer-term goal of $250M in 4Q27. The recent launch of two new products and the establishment of a permanent J-Code for IOPIDINE indicate the company's strong position in the market and potential for increased revenue. With a focus on growth and established partnerships with eye care centers in the US, Harrow is well-positioned to meet their revenue goals and expand their market presence.
Bears say
Harrow is seeing strong sales growth in Triesence, which could contribute significantly to net revenue and has potential for further expansion. Additionally, the permanent J code for Iopidine on July 1 may bring in more revenue from the relief of acute intra-ocular pressure increase during various procedures. However, the larger revenue impact from Iopidine is not expected until 2027.
This aggregate rating is based on analysts' research of Harrow Health Inc and is not a guaranteed prediction by Public.com or investment advice.
HROW Analyst Forecast & Price Prediction
Start investing in HROW
Order type
Buy in
Order amount
Est. shares
0 shares